Novel polypeptide screening and evolution method based on target protein

By de novo designing the peptide library and three-dimensional evolution method combined with one-bead-one-piece combination chemistry and microfluidic chip technology, the problems of low efficiency and poor stability of targeted peptide screening in the existing technology are solved, and efficient screening of target proteins is achieved and Improved peptide performance and is suitable for targeted therapy.

CN118895567APending Publication Date: 2024-11-05BEIJING INST OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211197916.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-04
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing targeted polypeptide screening methods have problems such as long periods, high cost, small throughput, inability to screen non-natural amino acids and other modified molecules, and unstable performance of targeted polypeptides screened under in vitro conditions in the physiological environment.

Method used

Using a de novo design of peptide library and three-dimensional evolution method, combined with one-bead-one-object combination chemistry method and microfluidic chip technology, through biotin labeling and magnetic bead sorting, use AIE molecular aggregation-induced luminescence performance to screen polypeptides with self-assembly potential and its affinity was detected by inverted fluorescence microscope and surface plasmon resonance.

Benefits of technology

The efficient screening of any target protein is achieved. The obtained targeted polypeptide has excellent performance in the real physiological environment, short cycle and high efficiency, and can achieve multivalent binding and anti-enzymatic decomposition, which is suitable for targeted therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118895567A_ABST
    Figure CN118895567A_ABST
Patent Text Reader

Abstract

The invention relates to a novel method for screening and evolving polypeptide and polypeptide assembly based on target protein. The method comprises the following steps: firstly, synthesizing a polypeptide library containing aggregation-induced emission (AIE) molecules by using a one-bead one-substance combinatorial chemical method, wherein the capacity of the library is more than 104; and screening and identifying the targeted polypeptide by using a'three-dimensional evolution 'strategy. Specifically, a polypeptide library is sequentially incubated in a tissue suspension carrying target protein and a suspension added with the target protein, and then target positive peptide beads are sorted by using a microfluidic core technology. Three-dimensional screening is carried out in a 10 * 10 microarray; in one-dimensional evolution, the AIE performance of TPE molecules is utilized to obtain peptide beads with self-assembly performance; the method comprises the following steps: in two-dimensional evolution, obtaining peptide beads with affinity to PD-L1 by using Cy5-labeled PD-L1, then splitting polypeptide by using a splitting solution, and obtaining a polypeptide sequence diagram by using in-situ MAlDI-TOF-MS; in three-dimensional evolution, polypeptide in the microarray is transferred to a bare gold chip in situ for in-situ SPRi affinity identification. And finally, carrying out Fomc solid-phase synthesis on the optimized polypeptide. According to the method, polypeptide with self-assembly and recognition functions can be screened for any target protein, and natural polypeptide, non-natural polypeptide and the like can be screened.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of targeted polypeptide screening, and in particular to a targeted polypeptide screening evolution method based on any target protein. Background Art

[0002] Molecular recognition plays a pivotal role in biosensing, early diagnosis of tumors and targeted cancer therapy. Developing new recognition molecules for different drug targets and establishing high-affinity and high-specificity recognition systems are important means to achieve "precision medicine". Targeted peptides refer to peptide molecules with high affinity and selectivity for target proteins. Compared with other types of molecules (such as nucleic acid aptamers, antibodies, small molecules, etc.), targeted peptides have the advantages of being designed and synthesized, low immunogenicity, and having recognition performance comparable to antibodies. Therefore, they have received widespread attention. At present, most targeted peptides are derived from natural sequences. In order to improve their performance, they need to be further modified. This method is not only cumbersome, but also often cannot ensure that a peptide sequence with excellent performance is obtained. At present, a variety of screening strategies have been developed to obtain targeted peptides, such as the classic phage display technology, but this method has problems such as long cycle, high cost, high labor and low throughput. The most important thing is that phage screening technology can only target natural amino acids and cannot screen non-natural amino acids and other modified molecules. The above problems seriously limit the application of this method. Combinatorial chemical screening can realize the screening of non-natural amino acids, which to some extent makes up for the shortcomings of phage screening, but it has a long cycle, low efficiency, and time-consuming analysis and identification. Secondly, most of the current screening strategies use recombinant proteins as targets to screen and identify peptides under in vitro conditions. However, the real physiological environment is extremely complex, the expression of target proteins is often complexly modified, and conditions such as pH are quite different from the screening environment, so it is impossible to ensure that the targeted peptides obtained under in vitro conditions continue to maintain their performance in the physiological environment. Therefore, the development of new screening methods is a key way to obtain high-performance targeted peptides.

[0003] Small molecule targeted peptides have the dilemma of monovalent binding to the target in the dynamic environment of the body, being unstable, and being easily degraded by enzymes. Especially for protein targets like immune checkpoint PD-L1, whose surface is rich in β-folded structure, the surface is large and flat, and the area can reach For this structure, it is difficult for small molecule targeting peptides to be stably bound to it. Bottom-up self-assembly is a unique property of peptide molecules. Under the joint action of a series of non-covalent bonds (hydrogen bonds, hydrophobic interactions, electrostatic interactions, and π-π stacking, etc.), peptide molecules can be designed to form highly ordered supramolecular nanostructures, such as nanotubes, nanofibers, and nanospheres. The formation of these nanoassemblies greatly increases its anti-enzymatic performance on the one hand, and can achieve multivalent binding to the target on the other hand. In addition, it can be used as a carrier to efficiently transport drugs and imaging agents to achieve multiple methods of combined diagnosis and treatment. Therefore, self-assembly is an effective way to improve the binding force and stability of targeting peptides. However, in order to achieve self-assembly, most of them are currently completed by splicing peptide units (i.e., assembly units, recognition units, etc.). The peptide molecules constructed in this way have achieved assembly and recognition to a certain extent, but there are problems such as the inability to coordinate between units and the single morphology of the nanostructure. Therefore, while fully integrating various functional units, achieving the self-assembly of targeted peptides has important application value. Summary of the invention

[0004] The purpose of the present invention is to provide a new method for screening and evolving targeting polypeptides and polypeptide assemblies, thereby providing a basis for obtaining high-performance targeting polypeptides.

[0005] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0006] In the first aspect, the present invention uses a de novo design method to design a peptide library that can simultaneously target PD-L1 and RBM38 proteins. The general formula of the peptide library is as follows:

[0007] TPE-SKDEEX18X17X16X15X14X13PX11X10PX8TX6X5X4DX2G

[0008] TPE is tetraphenylethylene with AIE properties; T and D residues are used to specifically recognize RBM38; the SKDEE sequence is used to promote the formation of α-helical structure; and the remaining residues are one of the hydrophilic or hydrophobic residues in natural amino acids.

[0009] Furthermore, X2, X8, X14, and X15 are one of asparagine and glutamine; X4 is one of glutamic acid and aspartic acid; X5 is one of tyrosine and phenylalanine; X6 is one of tyrosine and tryptophan; X10 is one of serine and threonine; X11 is one of isoleucine, valine, and tryptophan; X13 and X18 are one of phenylalanine, tryptophan, and tyrosine; X16 is one of lysine and histidine; and X17 is one of lysine, arginine, and histidine.

[0010] Furthermore, the “one bead one substance” combinatorial chemistry method was used to synthesize a library with a capacity of 10 5 Peptide library.

[0011] In a second aspect, the present invention provides a new strategy for optimizing target polypeptides using a three-dimensional evolutionary method.

[0012] Furthermore, the biotin-labeled target protein was incubated with streptavidin-labeled magnetic beads and streptavidin-labeled Cy5 to obtain PD-L1 protein with magnetic and fluorescent signals.

[0013] Furthermore, in one-dimensional evolution, the peptide library is first incubated with target-positive tissue lysate or cells to obtain peptides with self-assembly potential by utilizing the aggregation-induced emission properties of AIE molecules.

[0014] Furthermore, in the two-dimensional evolution, the peptide library was mixed and incubated with the PD-L1 protein with magnetic and fluorescent signals.

[0015] Furthermore, in a microfluidic chip platform, magnetic sorting was used to enrich peptide beads with binding potential to PD-L1 and immobilized them in a 10×10 microarray.

[0016] Furthermore, the peptide beads with AIE properties were identified under an inverted fluorescence microscope, and the peptides with self-assembly potential were obtained and their coordinates in the microarray were recorded.

[0017] Furthermore, peptide beads with Cy5 fluorescence were identified under an inverted fluorescence microscope to obtain peptides with affinity for PD-L1, and their coordinates in the microarray were recorded.

[0018] Furthermore, the peptide beads whose coordinates were repeated in the above two steps were used as further identification targets.

[0019] Furthermore, the polypeptides on the resin are cleaved, and secondary mass spectrometry detection and sequencing are performed using in situ mass spectrometry.

[0020] Furthermore, in the third-dimensional evolution, the peptides in the microarray were reprinted onto a bare gold chip, and surface plasmon resonance (SPRi) was used to detect in situ the affinity of the peptides for PD-L1.

[0021] Furthermore, the polypeptide sequence is: TPE-SKDEEWHKNNFPLSPNTYFDDNG, and it is named TAP.

[0022] The beneficial effects of the present invention are:

[0023] (1) The present invention can be used to screen targeting polypeptides for any target protein.

[0024] (2) The present invention uses a three-dimensional evolutionary strategy to screen the peptide library, and the resulting targeting polypeptide integrates multiple properties such as assembly and recognition.

[0025] (3) The present invention combines the one-bead-one-substance combinatorial chemistry method with microfluidic chip technology to enable the library capacity of up to 10 8 The peptide library can be screened with the characteristics of short cycle, high efficiency and reliable results.

[0026] (4) The present invention uses active systems such as tumor tissues or cells as the screening environment, and the obtained targeting polypeptides have better performance in the real physiological environment. Description of the drawings:

[0027] Figure 1 A de novo designed peptide library was used for the present invention.

[0028] Figure 2 It is a microfluidic chip peptide bead sorting platform.

[0029] Figure 3 It is a 10×10 microarray platform.

[0030] Figure 4 In one-dimensional evolution, tumor tissue lysate was used as the environment to screen self-assembling peptide beads, and in two-dimensional evolution, peptide beads with affinity for PD-L1 were detected.

[0031] Figure 5 It is an in situ MALDI-TOF-MS platform.

[0032] Figure 6 In situ SPRi detection of peptides in three-dimensional evolution. DETAILED DESCRIPTION

[0033] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0034] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0035] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0036] Example 1 Design and construction of the peptide library of the present invention

[0037] 1) Experimental materials and instruments

[0038] Tentagel resin, wang resin, N-methylmorpholine (NMM), trifluoroacetic acid (TFA), dichloromethane (DCM), ninhydrin, tetramethyluronium hexafluorophosphate (HBTU), vitamin C, hexahydropyridine, phenol, anhydrous ethanol, anhydrous ether, various Fmoc-amino acids, cyanogen bromide, streptavidin-labeled nanomagnetic beads, biotin-labeled PD-L1 protein, Cy5-labeled PD-L1 protein, skim milk, Tween-20, N,N-dimethylformamide, SPRi bare gold core were purchased from PLexera Biotechnology Co., Ltd., peptide synthesis tubes, shaker, circulating water vacuum pump, and rotary evaporator.

[0039] 2) Solvent preparation

[0040] Deprotection reagent - 20% piperidine: reaction solution - N-methylmorpholine, N,N-dimethylformamide = 1:24.

[0041] Lysis solution: trifluoroacetic acid (92.5%), triisopropylsilane (2.5%), ethanedithiol (2.5%), ultrapure water (2.5%);

[0042] Triketone test solution—— Triketone: Vitamin C: Phenol = 1:1:1

[0043] 3) Peptide library design and synthesis

[0044] The peptide library was constructed using a de novo design method. Our design goal is to obtain a targeting peptide that can target both Rbm38 and PD-L1 and can self-assemble. To this end, the general formula of the peptide library we designed is TPE-SKDEEX18X17X16X15X14X13PX11X10PX8TX6X5X4DX2G (TPE is tetraphenylethylene), in which the conserved residues T and D are used to specifically bind to the Rbm38 protein; the SKDEE sequence is used to induce the peptide chain to form an α-helical structure; the two P residues are used to cause the peptide chain to bend and thus increase contact with the target; the remaining random sites are hydrophilic residues, which are used to increase the affinity for PD-L1; finally, to indicate the self-assembly of the peptide, a TPE molecule with AIE properties is added to the N-terminus of the peptide chain. Peptide library design as follows Figure 1 shown.

[0045] The synthesis process proceeds from the carbon end to the nitrogen end. TentaGel resin (substitution degree 0.35mM / g) is used as a solid phase carrier, and the entire synthesis process is carried out in anhydrous DMF. In the coupling step, TentaGel resin is mixed with HBTU (4mM), Fmoc-amino acid (4mM) and 4mL0.4M NMM DMF solution, and the coupling time is 40 minutes. In the deprotection step, 20v / v% piperidine (dissolved in DMF) is used to remove the Fmoc group, and the deprotection time is 10 minutes. In the coupling step, the resin is divided equally according to the type of amino acid at each site, and then each part is coupled with a different amino acid. After the synthesis is completed, a cleavage reagent (95v / v% TFA, 2.5v / v% water and 2.5v / v% Tips) is introduced to cleave the side chain protecting group on each residue, and the cleavage time is 2 hours. The cleaved peptide library is washed alternately in DMF and DCM 3 times, then shrunk in methanol for 5 minutes, and vacuum-dried for standby use.

[0046] Example 2 Three-dimensional evolution of targeting peptides

[0047] (1) Peptide library pretreatment

[0048] The peptide library was swollen in PBS for 2.5 hours, then washed 3 times with PBS, blocked in 5% (m / v) skim milk at 37°C for 1 hour, and then washed 3 times with PBS. The washed peptide library was added to the target-positive tissue lysate or target-positive cell lysate and incubated at 37°C for 2 hours. Then the PD-L1 labeled with magnetic signals and the PD-L1 protein labeled with fluorescent signals were added to the lysate and incubated for another 2 hours.

[0049] (2) Microfluidic sorting

[0050] After the incubation, the peptide library containing the lysate was screened on a microfluidic chip using magnetic capture to screen the positive peptide library ( Figure 2 During the microfluidic screening, the flow rate was set at 60 μL / min, the sheath flow rate A was set at 10 μL / min, and the sheath flow rate B was set at 60 μL / min. After microfluidic screening, the positive peptide beads were collected into a 10×10 microarray for further analysis. The size of the microwells in the microarray was set to 40 μm×40 μm ( Figure 3 ).

[0051] (3) One-dimensional evolution of peptide library

[0052] After the collection, the microarray was subjected to the evolution of the peptide self-assembly performance under a confocal fluorescence microscope. Since the self-assembly of the peptides on the surface of the peptide beads will cause the TPE molecules to produce fluorescence, the confocal fluorescence microscope can be used to identify the peptides with self-assembly performance, and the coordinates of the peptide beads in the microarray can be recorded according to the intensity of the fluorescence signal ( Figure 4 a). The excitation wavelength of TPE is 420 nm and the emission wavelength is 460 nm.

[0053] (5) Two-dimensional evolution of peptide library

[0054] When the peptide on the peptide bead binds to the Cy5-labeled target protein PD-L1, the peptide bead is given red fluorescence. Therefore, the affinity between the peptide and PD-L1 can be identified based on the fluorescence signal. The coordinates of the peptide bead in the corresponding array are recorded according to the intensity of the fluorescence signal ( Figure 4 b) The excitation wavelength of Cy5 is 650 nm and the emission wavelength is 670 nm.

[0055] (6) Peptide library sequencing and digestion

[0056] In the above one-dimensional and two-dimensional evolution, peptides with the same coordinates have both self-assembly and recognition functions. By introducing cyanogen bromide lysis solution (30 mg / ml) into the microarray, the peptides were cleaved from the peptide beads and identified by secondary mass spectrometry ( Figure 5 ), and then use the Mascot database to extract the corresponding sequence information

[0057] (7) Three-dimensional evolution of peptide library

[0058] Surface plasmon resonance (SPRi) was used to detect the affinity between peptide and PD-L1 protein. Figure 6 ). The peptides in the microarray were in situ transferred to the gold chip by in situ transfer method, incubated overnight at 4°C in a humidified environment, then washed with 10×PBS for 10 minutes, then washed with 1×PBS for 10 minutes, and finally washed twice with deionized water for 10 minutes each. Then incubated overnight at 4°C in 5% skim milk, then washed with 10×PBS for 10 minutes, then washed with 1×PBS for 10 minutes, and finally washed twice with deionized water for 10 minutes each, dried with nitrogen, and loaded on the chip machine (Plexera HT surface plasmon resonance imaging system).

[0059] Affinity determination between peptide and PD-L1: The mobile phase passed through 1×PBS, 2×PBS, 0.625 nmol / L, 1.25 nmol / L, 2.5 nmol / L, 5 nmol / L, 10 nmol / L and 20 nmol / L of PD-L1 in sequence, and the SPRi signal was recorded and analyzed to obtain the affinity dissociation constant.

[0060] Affinity determination between the peptide and Rbm38 protein: the mobile phase passed through 1×PBS, 2×PBS, 8 nmol / L, 16 nmol / L, 34 nmol / L, 69 nmol / L, 138 nmol / L and 276 nmol / L of PD-L1 in sequence, and the SPRi signal was recorded and analyzed to obtain the affinity dissociation constant.

Claims

1. A method for screening polypeptides for a target protein, characterized in that: The screening method comprises: A general formula for designing a peptide library for any target protein is used, the peptide library is synthesized using the "one bead one object" combinatorial chemistry method, and finally the target peptide sequence is obtained using a three-dimensional evolution method. Preferably, the target protein is a target protein derived from a tumor or a virus-related protein; More preferably, the target proteins are Rbm38 (RNA binding motif protein 38) and PD-L1 (programmed cell death-ligand 1).

2. The polypeptide library design according to claim 1, characterized in that: Design methods include modification of natural peptides and de novo design; Preferably, the general formula of the peptide library is TPE-SKDEEX18X17X16X15X14X13PX11X10PX8TX6X5X4DX2G (TPE is tetraphenylethylene), wherein the conserved residues T and D are used to specifically bind to the Rb m38 protein; the SKDEE sequence is used to induce the peptide chain to form an α-helical structure; the two P residues are used to cause the peptide chain to bend and thus increase contact with the target; the remaining random sites are hydrophilic residues to increase affinity for PD-L1; and the TPE molecules are used to indicate the self-assembly of the polypeptide.

3. The method for synthesizing a polypeptide library according to claim 1, characterized in that The synthesis is carried out by using the "one bead one substance" combinatorial chemistry method; Preferably, the library capacity of the polypeptide library is 10 4 above; Preferably, the polypeptide library includes both natural amino acids and unnatural amino acids; Preferably, the polypeptide library comprises environmentally responsive molecules; More preferably, the environmentally responsive molecules include aggregation-induced emission (AIE) molecules, molecules that can indicate polypeptide assembly, such as Thioflavin T, and the like.

4. The polypeptide evolution method according to claim 1, characterized in that: The evolutionary method comprises three dimensions: in the first dimension, a polypeptide sequence capable of self-assembly is identified; in the second dimension, a polypeptide sequence having affinity for a target protein is identified; and in the third dimension, the affinity of the polypeptide for the target protein is determined.

5. The polypeptide evolution method according to claims 1 to 4, characterized in that: The peptide library was incubated with the target positive tissue suspension and the target protein in sequence, and the positive peptide beads were sorted using the microfluidic chip sorting method. The positive peptide beads were collected in a 10×10 microarray.

6. The polypeptide evolution method according to claims 1 to 5, characterized in that: In the first dimension, environmentally responsive molecules were used to obtain peptide beads with self-assembly properties under a confocal microscope, and the coordinates of the peptide beads in the array were recorded.

7. The polypeptide evolution method according to claims 1 to 6, characterized in that: In the second dimension, peptide beads with high affinity for the target protein were identified using Cy5-labeled PD-L1, and the coordinates of the peptide beads in the array were recorded.

8. The polypeptide evolution method according to claims 1 to 7, characterized in that: The peptides on the beads were cleaved with a lysis buffer, and then the peptide sequence map was obtained using in situ MA1DI-TOF-MS.

9. The polypeptide evolution method according to claims 1 to 8, characterized in that: In the third dimension, the peptides in the microarray are transferred in situ onto a bare gold chip and their affinity to the target protein is measured using surface plasmon resonance (SPR).